CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
Autoantibody-producing plasma cells are frequently resistant to conventional immunosuppressive treatments and B-cell depletion therapy. As a result of this resistance, autoreactive plasma cells survive conventional therapy, resulting in persistent autoantibody production and inflammation. CD38 is hi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-12-01
|
| Series: | Journal of Translational Autoimmunity |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S258990901930022X |